Patents by Inventor Yoko Fukui

Yoko Fukui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10744351
    Abstract: A mask is provided that can inactivate viruses adhering thereto even in the presence of lipids and proteins regardless of whether or not the viruses have an envelope. The mask can inactivate viruses adhering thereto and includes a mask body provided with a member used when the mask is worn and virus inactivating fine particles having a virus inactivating ability and held by the mask body. The virus inactivating fine particles are particles of at least one selected from the group consisting of platinum(II) iodide, palladium(II) iodide, silver(I) iodide, copper(I) iodide, and copper(I) thiocyanate.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: August 18, 2020
    Assignee: NBC MESHTEC, INC.
    Inventors: Yoshie Fujimori, Youhei Jikihara, Tetsuya Sato, Yoko Fukui, Tsuruo Nakayama
  • Publication number: 20200215093
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Patent number: 10632139
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: April 28, 2020
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Publication number: 20180353531
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 13, 2018
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Patent number: 10071113
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: September 11, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Publication number: 20170020910
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Application
    Filed: October 10, 2016
    Publication date: January 26, 2017
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Akiko SAKATANI, Tatsuo IKEI, Koji INAGAKI, Masatsugu NAKAMURA, Kazuhiro HOSOI, Mikiko SAITO, Masaki SONODA, Yoko FUKUI, Mitsuaki KUWANO
  • Publication number: 20160324892
    Abstract: [Problem] To provide a bactericidal composition for bacterial skin disease against which it is difficult for bacteria that cause bacterial skin disease to acquire drug resistance. [Solution] A bactericidal composition for bacterial skin disease that is characterized by including silver iodide in the form of nanoparticles having a particle size of 1-100 nm, inclusive, iodide ions, a water-soluble polymer, and an organic acid having a carboxyl group, and/or a salt of said acid, wherein the molar ratio of silver to iodide ions in the silver iodide is 1:1-1:1000.
    Type: Application
    Filed: February 6, 2015
    Publication date: November 10, 2016
    Applicant: NBC MESHTEC INC.
    Inventors: Yoko FUKUI, Eri MAZUYAMA, Yoshie FUJIMORI, Tomokazu NAGAO, Tsuruo NAKAYAMA
  • Patent number: 9486529
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: November 8, 2016
    Assignee: SANTEN PHARMCEUTICAL CO., LTD.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Patent number: 9380785
    Abstract: To provide an antiviral resin member which can efficiently inactivate viruses and has excellent sustainability. An antiviral resin member comprising a resin, an antiviral agent, and a surface potential-controlling agent, characterized in that the surface potential-controlling agent causes the surface potential of the antiviral resin member to shift to a value on the positive side of the potential of the resin alone.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: July 5, 2016
    Assignee: NBC MESHTEC, INC.
    Inventors: Shinji Kurahashi, Nobukazu Motojima, Yoko Fukui, Tsuruo Nakayama
  • Patent number: 9155309
    Abstract: A virus inactivating sheet is provided that can inactivate viruses adhering thereto even in the presence of lipids and proteins regardless of whether or not the viruses have an envelope. The virus inactivating sheet can inactivate viruses adhering thereto and includes a sheet body, and monovalent copper compound fine particles and/or iodide fine particles that are held by the sheet body. The virus inactivating sheet can inactivate various viruses. These viruses can be inactivated even in the presence of lipids and proteins.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: October 13, 2015
    Assignee: NBC MESHTEC, INC.
    Inventors: Yoshie Fujimori, Youhei Jikihara, Tetsuya Sato, Yoko Fukui, Tsuruo Nakayama
  • Patent number: 9045855
    Abstract: Disclosed is an anti-viral member which can inactivate a virus. Specifically disclosed is an anti-viral member which is characterized by comprising a base material, univalent copper compound microparticles, and inorganic microparticles which are provided for the purpose of retaining the univalent copper compound microparticles on the base material and each of which has a silane monomer bound to the surface thereof via a chemical bond, wherein the inorganic microparticles are bound to one another via chemical bonds formed between the silane monomers provided on the surfaces thereof, and each of the inorganic microparticles is bound to the base material via a chemical bond between the silane monomer and the base material to form spaces in which the univalent copper compound microparticles are to be retained.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: June 2, 2015
    Assignee: NBC Meshtec, Inc.
    Inventors: Yoshie Fujimori, Tsuruo Nakayama, Yoko Fukui
  • Publication number: 20150072951
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Application
    Filed: March 25, 2013
    Publication date: March 12, 2015
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Publication number: 20140367263
    Abstract: [Problem] To provide an anti-virus aluminum member capable of minimizing secondary infection by deactivating viruses in a short period of time even when viruses adhere thereto, regardless of whether a viral envelope is present, and useful for application in door knobs, handrails, air-conditioner fins or the like. [Solution] An anti-virus aluminum member capable of deactivating viruses that adhere thereto is characterized in that an anti-virus inorganic compound is present in the pores of an anodized membrane provided with multiple pores and obtained by anodizing aluminum or an aluminum alloy.
    Type: Application
    Filed: September 7, 2012
    Publication date: December 18, 2014
    Inventors: Yoko Fukui, Tsuruo Nakayama, Yoshie Fujimori
  • Publication number: 20140221306
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent, formation of insoluble precipitates found in Diquafosol ophthalmic solution during its storage, as well as deterioration of the filtration performance in the course of production (filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, enhancement of preservative effectiveness has been confirmed. Accordingly, the present invention provides Diquafosol ophthalmic solution having physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient. Particularly in the course of production, the solution can be subjected to efficient filtration sterilization. Moreover, the solution has excellent preservative effectiveness.
    Type: Application
    Filed: December 27, 2011
    Publication date: August 7, 2014
    Applicant: Santen Pharmaceutical Co. Ltd
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Publication number: 20140127321
    Abstract: To provide an antiviral resin member which can efficiently inactivate viruses and has excellent sustainability. An antiviral resin member comprising a resin, an antiviral agent, and a surface potential-controlling agent, characterized in that the surface potential-controlling agent causes the surface potential of the antiviral resin member to shift to a value on the positive side of the potential of the resin alone.
    Type: Application
    Filed: July 6, 2012
    Publication date: May 8, 2014
    Applicant: NBC MESHTEC, INC.
    Inventors: Shinji Kurahashi, Nobukazu Motojima, Yoko Fukui, Tsuruo Nakayama
  • Publication number: 20120192876
    Abstract: A mask is provided that can inactivate viruses adhering thereto even in the presence of lipids and proteins regardless of whether or not the viruses have an envelope. The mask can inactivate viruses adhering thereto and includes a mask body provided with a member used when the mask is worn and virus inactivating fine particles having a virus inactivating ability and held by the mask body. The virus inactivating fine particles are particles of at least one selected from the group consisting of platinum(II) iodide, palladium(II) iodide, silver(I) iodide, copper(I) iodide, and copper(I) thiocyanate.
    Type: Application
    Filed: September 30, 2010
    Publication date: August 2, 2012
    Inventors: Yoshie Fujimori, Youhei Jikihara, Tetsuya Sato, Yoko Fukui, Tsuruo Nakayama
  • Publication number: 20120171276
    Abstract: A virus inactivating sheet is provided that can inactivate viruses adhering thereto even in the presence of lipids and proteins regardless of whether or not the viruses have an envelope. The virus inactivating sheet can inactivate viruses adhering thereto and includes a sheet body, and monovalent copper compound fine particles and/or iodide fine particles that are held by the sheet body. The virus inactivating sheet can inactivate various viruses. These viruses can be inactivated even in the presence of lipids and proteins.
    Type: Application
    Filed: October 4, 2010
    Publication date: July 5, 2012
    Inventors: Yoshie Fujimori, Youhei Jikihara, Tetsuya Sato, Yoko Fukui, Tsuruo Nakayama
  • Publication number: 20110262513
    Abstract: Disclosed is an anti-viral member which can inactivate a virus. Specifically disclosed is an anti-viral member which is characterized by comprising a base material, univalent copper compound microparticles, and inorganic microparticles which are provided for the purpose of retaining the univalent copper compound microparticles on the base material and each of which has a silane monomer bound to the surface thereof via a chemical bond, wherein the inorganic microparticles are bound to one another via chemical bonds formed between the silane monomers provided on the surfaces thereof, and each of the inorganic microparticles is bound to the base material via a chemical bond between the silane monomer and the base material to form spaces in which the univalent copper compound microparticles are to be retained.
    Type: Application
    Filed: December 28, 2009
    Publication date: October 27, 2011
    Applicant: NBC MESHTEC, INC.
    Inventors: Yoshie Fujimori, Tsuruo Nakayama, Yoko Fukui